Global Macitentan (CAS 441798-33-0) Market Size By Type (99% Purity Type,98% Purity Type), By Application (Generic Drug, Original Frug), By Region, And Segment Forecasts, 2023 to 2032

The Global Macitentan (CAS 441798-33-0) Market was valued at USD 1.1 billion in 2023 and is projected to surpass USD 2.3 billion by 2031, growing at a CAGR of 9.6% during the forecast period from 2023 to 2031. Macitentan, an endothelin receptor antagonist (ERA), is widely used for treating pulmonary arterial hypertension (PAH). Its ability to improve exercise capacity and delay disease progression has positioned it as a preferred option among PAH therapies. The market is witnessing significant growth due to rising cases of PAH globally, increasing awareness about rare cardiopulmonary conditions, and the steady expansion of specialty drug access in emerging economies.

Drivers:

Rising Prevalence of Pulmonary Arterial Hypertension:

An increasing incidence of PAH worldwide, especially among aging populations, is a major driver. Enhanced diagnostic capabilities and broader screening protocols are also enabling earlier and more accurate diagnoses.

Favorable Regulatory Approvals:

Continued support from regulatory bodies like the FDA and EMA for macitentan-based therapies is fueling growth. These approvals are extending beyond PAH to other cardiovascular indications, expanding the drug’s commercial potential.

Adoption of Combination Therapies:

Macitentan is increasingly used in combination with other PAH treatments like phosphodiesterase-5 inhibitors and prostacyclins. This has proven clinically beneficial, boosting the drug's uptake and market volume.

Restraints:

High Treatment Costs:

Macitentan is a high-cost specialty pharmaceutical, limiting accessibility in low- and middle-income countries. The absence of generic alternatives further contributes to cost-related barriers.

Adverse Side Effects:

Although effective, macitentan carries potential side effects including liver enzyme elevation, anemia, and teratogenicity, which can deter its usage and demand close monitoring of patients.

Opportunity:

Expansion into Emerging Markets:

Countries in Asia-Pacific and Latin America present lucrative growth opportunities owing to rising healthcare spending, improving drug distribution infrastructure, and increased awareness of PAH.

Development of Generic and Biosimilar Versions:

Patent expirations and growing interest from generic manufacturers are expected to diversify the competitive landscape, offering affordable options and expanding market penetration.

Exploration in New Indications:

Ongoing clinical trials are evaluating macitentan for fibrotic diseases and other cardiovascular conditions, potentially opening up new therapeutic avenues.

Market by System Type Insights:

The Oral Macitentan segment dominated the market in 2023 and is projected to retain its lead during the forecast period. Oral formulations are preferred for chronic conditions due to better patient compliance and ease of administration. As home-based treatment models gain popularity, the demand for convenient oral ERAs like macitentan continues to rise.

Market by End-use Insights:

In 2023, the Hospitals & Specialty Clinics segment emerged as the largest end-user, driven by the need for specialized monitoring and treatment protocols associated with macitentan therapy. However, the Retail Pharmacies segment is expected to grow significantly due to increasing outpatient prescriptions and the decentralization of chronic disease care.

Market by Regional Insights:

North America held the largest share in 2023, bolstered by advanced healthcare infrastructure, favorable reimbursement frameworks, and high awareness of PAH. Europe followed closely, supported by active clinical trials and streamlined drug access across countries. Asia-Pacific is projected to witness the highest CAGR during the forecast period, attributed to improvements in healthcare access and rising PAH prevalence.

Competitive Scenario:

Key players operating in the global macitentan market include Johnson & Johnson (through Actelion Pharmaceuticals), Gilead Sciences, Bayer AG, GlaxoSmithKline plc, and United Therapeutics. These companies are investing in expanded label indications, strategic licensing agreements, and patient-assistance programs. For example:

In 2023, Johnson & Johnson initiated a Phase III trial exploring macitentan in combination with ambrisentan for fibrotic lung disorders.

In 2024, United Therapeutics announced a partnership to co-develop oral ERA therapies for pediatric PAH indications.

In 2025, generic drug manufacturers in India received regulatory approval to begin trials on macitentan generics, signaling future cost reductions.

Scope of Work – Global Macitentan (CAS 441798-33-0) Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2031) USD 2.3 billion

CAGR (2023–2031) 9.6%

Market Segments By System Type (Oral, Injectable), By End-use (Hospitals, Clinics, Retail Pharmacies), By Region

Growth Drivers Rising prevalence of PAH, Combination therapy adoption, Regulatory support

Opportunities Emerging markets, Generic expansion, New indications exploration

Key Market Developments:

2023 – Johnson & Johnson expanded its global PAH education initiative to include 12 additional countries in Africa and Asia.

2024 – EMA approved an expanded label for macitentan to include PAH associated with connective tissue diseases.

2025 – Bayer AG entered a joint research agreement with a Japanese pharma firm to evaluate novel ERAs based on macitentan’s molecular framework.

FAQs:

1) What is the current market size of the Global Macitentan (CAS 441798-33-0) Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Macitentan Market?

The major growth driver is the increasing prevalence of pulmonary arterial hypertension (PAH) and favorable regulatory support.

3) Which is the largest region during the forecast period in the Global Macitentan Market?

North America holds the largest market share during the forecast period.

4) Which segment accounted for the largest market share in Global Macitentan Market?

The Oral Macitentan segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Macitentan Market?

Key players include Johnson & Johnson, Gilead Sciences, Bayer AG, GlaxoSmithKline plc, and United Therapeutics.